GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Jungla, of course the share price expects the revenue to be in line with broker forecasts. That’s all there is to go off. No one knows whether the revenue will be £600,500,400,300,200mil, the market will react on the day of the trading update.
This is why companies announce if they are going to be over or above expected figures. GM left this wide open with a base of greater than H1. It could easily be in line with shaunp’s spreadsheet, it may also be £200mil.
From Routy on Telegram:
Just how undervalued is Novacyt vs. Biosynex??
Biosynex around 15% ebidta and about 23 P/E ratio
Nova about 80% ebidta and currently about 4 P/E ratio
On a like for like Novacyt is OVER 5 times undervalued ie. it should be over £50 to match Biosynex.
(Novacyt’s PE of 4 is based on a low £200 million earnings and £800 million MCAP)
Hartlebury, you see I think the company would need to announce it. It’s highly price sensitive information, if someone from the company or DHSC spoke about about the fact it hadn’t been extended the share price would be impacted, hence an RNS.
In the same way the company RNS’d that the french weren’t willing to reimburse the tests last year.
Kaeren, this answers your question from yesterday.
For Pfizer and Moderna, which produce theirs using genetic code called mRNA, it could be as basic as changing the genetic code on a computer and regenerating all of the RNA samples.
For Oxford and Janssen, however, which attach part of the real coronavirus to a living cold virus from a chimp, the companies must go through the process of growing all of these natural components, which slows down development. It takes Oxford around three months to make a batch.
We know all too well that predicting numbers for a company like Novacyt is extremely difficult. Many will agree with us about our expectations, but some will not at all. That is why we want to make it clear that this is absolutely not investment advice to you. In any case, we will continue to hold on to our shares! In a year's time we will see whether our expectations have actually come true.
A hit. That was our blog on February 1, 2020. Almost a year ago, we tipped Novacyt stock for its enormous price potential, after the company took the lead in developing a test for the corona virus. The share price rose that day from EUR 0.25 to EUR 0.45, or a gain of 81%. Many thought we were crazy when we set a target price of EUR 7 for this stock. Once the stock was discovered last year, it exploded to EUR 14. After a pause in the upward trend around EUR 8, the share has now returned to EUR 12. In our opinion, this is the start of a second price explosion. The company is in good shape and with the new corona mutations, another turnover / profit explosion can be expected. Our target price is EUR 45 for the coming year.
The small company Novacyt has suddenly become a big boy due to the corona pandemic. Where the turnover for 2019 was only EUR 13 million, resulting in a small loss, the turnover for 2020 will be at least EUR 150 million. And we think that is still on the meager side. Sales for the first half of last year amounted to EUR 72 million with EPS of 0.61. In the second half of the year, the number of tests only increased further. That is why we believe that the expectations that the CEO gave last year of a turnover of at least EUR 150 million will be exceeded. We are thinking of an EPS of EUR 2 over last year.
The corona virus mutates. It seems like this comes as a surprise to the world, while viruses are generally known to always mutate. The British corona mutant is now in the news. Then there was a South African mutant. Now it turns out there is also a Brazilian and German mutant. This just goes on and on. And the tests have to be adjusted accordingly. Novacyt is developing new tests for the mutants. The world seems to assume that corona will soon be over, now that there are several vaccines and people have already been vaccinated and are being vaccinated on a large scale. Multiple studies show that corona will likely rule our lives for years to come. Although that is terrible for everyone, there are companies that profit from this. Novacyt is at the forefront of taking advantage of this. This year, but also in the coming years, testing will be indispensable. That is not only testing in case of complaints, but also when traveling by airplanes, trains, buses, etc., etc. It will also not surprise us if you will be tested in the coming years when you visit a museum, a concert, a cinema or a soccer game. The number of tests we now see worldwide will only increase.
Based on further revenue growth and thus profit growth, we think there is a lot of potential in Novacyt's share price. If Novacyt presents a EPS of EUR 2 for 2020, at a price of EUR 12, that would mean a price earnings ratio of 6. In 2021 we expect an EPS of EUR 3. We value a stock like Novacyt, based on the risk of the product. and period-related revenue / profit explosions, at 15. That would mean a target price of EUR 45 for this year.
https://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2021/Thermo-Fisher-Scientific-to-Acquire-Point-of-Care-Molecular-Diagnostics-Provider-Mesa-Biotech/default.aspx
From telegram. Revenues of $45million and being acquired for $450million. The smaller companies are getting snapped up.
https://www.usaspending.gov/search/fc6037575fdfb57cf6aaea77318b67cf
Not sure if this has been posted before but provides info on USA government spending. I can’t seem to gauge anything from it but if anyone has a better idea of who our OEM could be with, they may be able to make some connections.
Will also be worth keeping an eye on following the tradition to Biden this week when the new COVID package is rolled out.
Kaeren I read a few weeks ago that the Pfizer vaccine (as its mRNA) can be altered within a few weeks if a new strain evades the current vaccine, that’s because of the new technology used.
The AZN vaccine isn’t as quick, I’m not sure of timelines but as it uses the harmless weaker version of the virus it takes longer to develop.
Obviously all of the above relies on the MHRA approving the changes without further trials.
I can imagine production, roll out and distribution would take a lot longer.
Porky, I find it quite amusing that the (UK) always says the US is far less regulated than us in Europe. It seems the US have actually seen some sense and now the (UK) is lagging behind with poor regulation for testing.
I’ll be very intrigued about the US OEM that we’ve heard nothing about for 9 months.
Earth, I hope it plans out for you and you get the knee surgery. I have a similar exit point.
On a similar note I have to say this is one of the best BB I have been on, similar to the GGP one.
Last week I briefly traded ARB and was shocked how rude, unwelcoming the BB was. Keep it up ladies and gents, it’s a really nice environment to be around and hopefully we are all rewarded. Have a good weekend, see you 7am Monday to see what GM brings.
https://twitter.com/Blad3sharp/status/1349814618827485190?s=20
Courtesy of bladesharp.